Markets
Summit Sinks 16% as FDA Declines Its Lung Cancer Drug
Summit Therapeutics fell 16.47% to $11.82 on November 16, 2026 after the FDA issued a complete response letter declining to approve ivonescimab for lung cancer.
Summit Therapeutics bet the company on one drug, and on Monday the US regulator said not yet. The Food and Drug Administration issued a complete response letter for ivonescimab, Summit's treatment for a form of non-small cell lung cancer, saying it cannot approve the application in its current form. The shares fell as much as 20% before the open and closed 16.47% lower at $11.82, a 52-week low.
The problem was survival. Ivonescimab, an antibody that blocks both the PD-1 immune checkpoint and the VEGF protein that feeds tumour blood vessels, was licensed from China's Akeso. In Summit's late-stage HARMONi trial it extended progression-free survival, the time patients live before the cancer worsens, but the improvement in overall survival was not statistically significant. The FDA said substantial evidence of effectiveness was "not established," a sign that for this setting it wants to see patients live longer, not only stay stable for longer.
Analysts split on how much was already priced in. Barclays cut its price target to $18 from $20 and kept an equal-weight rating, saying the letter itself had limited direct effect on its valuation but that the agency might set a higher bar for the rest of the lung-cancer programme. Citi trimmed its target to $42 from $43 and kept a buy. Jefferies reiterated a buy and a $30 target, arguing the rejection had been largely expected. The stock had already lost about a fifth of its value in the previous 20 sessions and more than 30% this year.
Summit said it will keep developing ivonescimab in other settings, including first-line lung cancer and colorectal cancer, where trials are still running. That leaves the company's value resting on studies whose results are still to come, and it may need to raise money to fund them, which for a stock at a yearly low means dilution for existing holders.
The same session showed the other side of binary biotech news. CG Oncology jumped 13.95% after its PIVOT-006 trial in bladder cancer met its main goal with a 68% lower risk of recurrence, and Helus Pharma fell 13.53% even though its depression trial succeeded, because of three serious drug-related side effects. In a market falling on AI worries, each of these stocks moved on its own data.
For traders, the lesson is about sizing rather than prediction. A regulatory decision or trial readout can move a single-product company 15% to 50% in a morning, before any stop-loss order can help, because the stock gaps through it at the open. Positions in such names are usually kept small enough that the worst plausible outcome is survivable, which is what diversification is for.